Alzinova Ab · OMXSTO:ALZ
Alzinova Ab — Investor Presentation (March 2026)
32 slides from Alzinova Ab's investor presentation, March 2026
Slide 1: Alzinova Company presentation March 2026
We will make it possible for Alzheimer's patients Alzinova to live an independent and active life Company presentation | March | 2026 ©2026 Alzinova AB (publ), All rights reserved
Slide 2: Forward looking statements
Forward looking statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate
Slide 3: Imagine if there was a vaccine against Alzheimer's disease
Imagine if there was a vaccine against Alzheimer's disease ©2026 Alzinova AB (publ), All rights reserved
Slide 4: Alzinova is developing the first specific vaccine against Alzheimer's disease
Swedish biopharma company | Based in Gothenburg Founded 2011 Alzinova is High unmet medical need for Alzheimer’s disease developing the – huge market opportunity first specific Innovative science & proprietary technology enables development of vaccine against disease-modifying treatments for Alzheim
Slide 5: Alzheimer's disease
Alzheimer’s disease • Slowly progressing disease • Caused by toxic formations in the brain called oligomers – consists of Aβ-42 peptide • Destroys brain structures Memory Delusions Loss of loss, & poor Depression Agitation independent Cause of confusion judgement life death • Need for targeted treat
Slide 6: Alzheimer's disease – huge unmet medical need
Alzheimer’s disease – huge unmet medical need Dementia >55 million people suffer from dementia Impacts >150 million people in 2050 quality of life US $1.3 trillion (US $2.8 trillion by 2030) Patients, families, Annual cost care givers 60-70% are Alzheimer’s patients World Alzheimer’s Report 2015, 20
Slide 7: Unmet medical need
Cognitive and physical decline, leads to increased dependency on Individual caregiving and later full-time care. Unpaid family and friend caregivers can experience physical, financial Caregiver & emotional strains. Unmet Elderly care requires institutionalized housing, managing health medical need H
Slide 8: >100 million people will suffer from Alzheimer's in 2050
>100 million people will suffer from Alzheimer’s in 2050 ©2026 Alzinova AB (publ), All rights reserved
Slide 9: Enormous market potential
Enormous market potential Alzheimer’s therapeutics market > US $13 billion by 2028 Substantial market 2 out of 7 predicted blockbusters by 2026 are new anti-Alzheimer’s drugs with potential for US $1.7 - 4.5 billion projected annual revenue Alzinova Market growth driven by introduction of novel ther
Slide 10: Potential breakthrough in Alzheimer's
Potential breakthrough in Alzheimer’s ✓ ✓ ✓ High unmet medical & market potential for disease-modifying treatments of Alzheimer’s disease Short-term goal: Mid-term goal: Long-term goal: First clinical trial targeting oligomers with a ALZ-101 Initiate Phase 2 in 2026 Bring to market in partners
Slide 11: Alzinova's business model – develop, document, prepare, partner & bring to market
Develop breakthrough disease-modifying treatments based on proprietary AβCC technology Document safety and tolerability in patients with Alzheimer’s disease Alzinova’s business model – develop, document, Prepare (in parallel) for phase 2 to optimize the candidates value prepare, partner & bring to m
Slide 12: Our candidates for treating Alzheimer's disease
Our candidates for treating Alzheimer’s disease ©2026 Alzinova AB (publ), All rights reserved
Slide 13: AβCC peptide technology targeting toxic oligomers
Alzinova’s AβCC peptide technology enables high precision, with antibodies specifically targeting the toxic oligomers Aβ – amyloid-beta ©2026 Alzinova AB (publ), All rights reserved
Slide 14: Two differentiated, oligomer-specific products based on the same proprietary technology
Two differentiated, oligomer- specific products based on the same proprietary technology • Highly specific disease modifying treatments, directed towards the toxic accumulations of amyloid beta in the brain • Opportunity to become effective and well tolerated treatments to halt and prevent Alzheimer
Slide 15: ALZ-101 represent a potential breakthrough in treating Alzheimer's Disease
ALZ-101 represent a potential breakthrough in treating Alzheimer's Disease • The body generates specific antibodies against toxic oligomers ALZ-101 vaccine • High patient compliance (few booster doses) • Long-acting • Preventive treatment possible • Large potential patient population ©2026 Alzinova
Slide 16: ALZ-201 a complement to the vaccine ALZ-101
ALZ-201 a complement to the vaccine ALZ-101 in treating Alzheimer's Disease • Unique binding profile for targeting toxic oligomers ALZ-201 monoclonal antibody • Several potential uses for the antibody: − complement to the vaccine ALZ-101 for patients who, for various reasons, need higher levels of a
Slide 17: Improving quality of care – for more patients
Improving quality of care – for more patients X1 X 50 Based on Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost. Sources: SCB Statistics Sweden, Swedish regional healthcare cost ©2026 Alzinova AB (publ), All rights reser
Slide 18: Alzinova's product pipeline offers complementary ways to fight Alzheimer's Disease
Alzinova's product pipeline offers complementary ways to fight Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Major Milestone ALZ-1011) therapeutic Positive results from vaccine phase 1b-study - Jan 2026, Phase 2 started 2025 ALZ-2012) monoclonal TBD “Phase 1 ready” anti
Slide 19: Advantages of an Oligomer-Specific Approach compared to Traditional Treatments
The Advantages of an Oligomer-Specific Approach compared to Traditional Treatments Alzinova Other actors Targeted treatment – oligomer specific Target plaques Vaccine Non-specific treatments Antibody - as a complement to the vaccine Often complicated drug treatments Fast, effective and uncomplicat
Slide 20: ALZ-101 – favourable profile with best-in-class opportunity
ALZ-101 – favourable profile with “best-in-class” opportunity ALZ-101 Donanemab Lecanemab Companies Alzinova Eli Lilly BioArctic/Eisai/Biogen Primary target Aβ oligomers plaque (P-Glu3-Aβ) Aβ monomers/fibrils/oligomers –> good efficacy +++ (potential) + + Compliance +++ + + Low cost* +++ ++ + Low so
Slide 21: Alzinova's ALZ-101 Phase 1b-study
Alzinova’s ALZ-101 Phase 1b-study ©2026 Alzinova AB (publ), All rights reserved
Slide 22: ALZ-101 Phase 1b Clinical Study in Patients with Alzheimer's Disease
ALZ-101 Phase 1b Clinical Study in Patients with Alzheimer’s Disease • Study Design: Double-blind, randomized, placebo-controlled study on safety, tolerability and immunogenicity • Part A1 – ALZ-101 (125 and 250 μg) or placebo, given at weeks 0, 4, 8 and 16, if not eligible for Part B, follow-up for
Slide 23: Strong data from phase 1b study
Strong data from phase 1b study Favourable safety and a robust immune response • ALZ-101 continues to show a favorable safety and tolerability profile after at least 84 weeks of study participation. • The immune response from vaccination with ALZ-101 is robust and long-lasting in more than 95% of pa
Slide 24: Phase 2 Preparations
Phase 2 Preparations Interactions with Regulatory Authorities – FDA and EMA • IND cleared and Fast track Designation granted. • EMA submissions in progress. Comprehensive preparation work • Study design and protocol in place. • Worldwide Clinical Trials selected as CRO for Phase 2. • Intellectual pr
Slide 25: Corporate & Finance
Corporate & Finance ©2026 Alzinova AB (publ), All rights reserved
Slide 26: Experienced & Committed team
Experienced & Committed team Tord Labuda, M.Sci., PhD Anders Sandberg, PhD Erik Kullgren Margareth Jorvid Chief Executive Officer Chief Scientific Officer Chief Financial Officer Head of Regulatory Affairs >15 years experience from Co-Founder >25 years experience within >30 years experience in senio
Slide 27: Board of Directors with extensive pharma and biopharma experience
Board of Directors with extensive pharma and Julian Aleksov Anders Blom Per-Göran Gillberg, PhD biopharma Chairman Member Member experience >25 years experience in finance and international development within >25 years experience in international finance and business development in 35 years experien
Slide 28: Capitalization table, summary of shares and options
Capitalization table, summary of shares and options Shareholders, as per 30 September 2025: Name No. of shares Capital, % Maida Vale Capital AB 17,558,901 16.83% Försäkrings AB Avanza Pension 7,735,234 7.41% Nordnet Pensionsförsäkring AB 3,912,152 3.75% Patrik Ahlvin 3,200,000 3.07% Market cap Åland
Slide 29: Financial information – Key figures, Jan-September 2025
Financial information Key figures, for Jan-September 2025 (Jan-Sep 2024) Total balance sheet Cash balance Cashflow Result Equity ratio 137 0,5 -15 -20 93% (28) (-14) (140) MSEK (1) MSEK MSEK (93%) MSEK • Mainly invested in capitalized costs for R&D, focus on present ALZ-101 phase 1 study and prepari
Slide 30: Product pipeline and value inflection points
Product pipeline and value inflection points Discovery Pre-clinical Clinical phase NDA/MAA Near-term data inflection points for ALZ-101 Strategic ALZ-101 (Vaccine) Phase 1b Phase 2 – 2026+ Phase 3 partnerships Portfolio ALZ-201 Phase 1 enhancements New innovative discovery projects NDA: New Drug App
Slide 31: Investment highlights
Investment highlights Alzinova’s promising candidates address vast unmet medical needs with potential for significant societal costs reductions compared with current treatments Data show that the unique specificity of Alzinova’s vaccine (ALZ-101) and the monoclonal antibody (ALZ-201) provides “best-
Slide 32: Alzinova
CEO Tord Labuda Alzinova Email: tord.labuda@alzinova.com Phone: +46 70-838 23 23 www.alzinova.com https://www.linkedin.com/company/alzinova-ab/ ©2026 Alzinova AB (publ), All rights reserved